Low-level laser therapy can reduce lipopolysaccharide-induced contractile force dysfunction and TNF-alpha levels in rat diaphragm muscle

Lasers Med Sci. 2006 Dec;21(4):238-44. doi: 10.1007/s10103-006-0405-y. Epub 2006 Oct 11.

Abstract

Our objective was to investigate if low-level laser therapy (LLLT) could improve respiratory function and inhibit tumor necrosis factor (TNF-alpha) release into the diaphragm muscle of rats after an intravenous injection of lipopolysaccharide (LPS) (5 mg/kg). We randomly divided Wistar rats in a control group without LPS injection, and LPS groups receiving either (a) no therapy, (b) four sessions in 24 h with diode Ga-AsI-Al laser of 650 nm and a total dose of 5.2 J/cm2, or (c) an intravenous injection (1.25 mg/kg) of the TNF-alpha inhibitor chlorpromazine (CPZ). LPS injection reduced maximal force by electrical stimulation of diaphragm muscle from 24.15+/-0.87 N in controls, but the addition of LLLT partly inhibited this reduction (LPS only: 15.01+/-1.1 N vs LPS+LLLT: 18.84+/-0.73 N, P<0.05). In addition, this dose of LLLT and CPZ significantly (P<0.05 and P<0.01, respectively) reduced TNF-alpha concentrations in diaphragm muscle when compared to the untreated control group.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Chlorpromazine / pharmacology
  • Diaphragm / chemistry*
  • Diaphragm / drug effects
  • Lipopolysaccharides*
  • Low-Level Light Therapy*
  • Male
  • Random Allocation
  • Rats
  • Rats, Wistar
  • Respiratory Insufficiency / chemically induced*
  • Respiratory Insufficiency / therapy*
  • Tumor Necrosis Factor-alpha / analysis*
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Lipopolysaccharides
  • Tumor Necrosis Factor-alpha
  • Chlorpromazine